The European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed the approval of Anoro, a combination of vilanterol and umeclidinium, as a treatment for chronic obstructive pulmonary disease. The drug was jointly developed by GlaxoSmithKline and Theravance. The committee also recommended the approval of umeclidinium, sold under the brand name Incruse, as a monotherapy for COPD.

Related Summaries